Program
Leucovorin
Also written as “leucovorin”, “Folinic acid” and “FLOT Chemotherapy”.
Its studies are mostly in Colorectal Neoplasms · Neoplasms · Pancreatic Neoplasms · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 21 companies.
Drug pageLeucovorin: every studyMany companies study it; this page follows only the 34 they lead. All 309 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 50 open or running | phase 3since May 9, 2007 | May 9, 2007 | none ahead |
| AstraZenecaits history only | 41 open or running | phase 2since Jul 17, 2003 | Jul 17, 2003 | Nov 9, 2027phase 2 · NCT07069712 |
| Bristol-Myers Squibbits history only | 40 open or running | phase 2since Jun 26, 2002 | Jun 26, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 30 open or running | phase 2since Feb 26, 2010 | Feb 26, 2010 | none ahead |
| Pfizerits history only | 21 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| 3SBioits history only | 11 open or running | phase 2since Jun 25, 2024 | Jun 25, 2024 | none ahead |
| AbbVieits history only | 11 open or running | phase 2since Oct 25, 2023 | Oct 25, 2023 | Dec 2026phase 2 · NCT06107413 |
| Adherex Technologiesits history only | 10 open or running | phase 2since Oct 27, 2010 | Oct 27, 2010 | none ahead |
| Aurobindo Pharmaits history only | 10 open or running | phase 2since Mar 28, 2014 | Mar 28, 2014 | none ahead |
| Cardiff Oncologyits history only | 10 open or running | phase 2since Feb 9, 2021 | Feb 9, 2021 | none ahead |
| Eli Lillyits history only | 10 open or running | phase 2since Jul 3, 2012 | Jul 3, 2012 | none ahead |
| Ipsenits history only | 10 open or running | phase 3since Sep 6, 2019 | Sep 6, 2019 | none ahead |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 3since Feb 20, 2023 | Feb 20, 2023 | none ahead |
| Leaf Verticalits history only | 10 open or running | phase 2since Jun 5, 2018 | Jun 5, 2018 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 3since Dec 4, 2015 | Dec 4, 2015 | none ahead |
| Merrimack Pharmaceuticalsits history only | 10 open or running | phase 3since Dec 14, 2011 | Dec 14, 2011 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jan 4, 2011 | Jan 4, 2011 | none ahead |
| Oncolytics Biotechits history only | 10 open or running | phase 1since Jan 7, 2011 | Jan 7, 2011 | none ahead |
| Swedish Orphan Biovitrumits history only | 10 open or running | phase 2since Feb 14, 2006 | Feb 14, 2006 | none ahead |
| TTY Biopharmits history only | 10 open or running | phase 2since Apr 12, 2018 | Apr 12, 2018 | none ahead |
| Wellstat Therapeuticsits history only | 10 open or running | phase 1since Sep 4, 2002 | Sep 4, 2002 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical, Parexel, Halozyme Therapeutics, BioLineRx, Axis Clinicals and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Jun 26, 2002.
- Mar 28, 2014Aurobindo Pharma’s first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to Aurobindo PharmaAurobindo Pharma · NCT02106650 · 36 enrolled · United States
- Dec 4, 2015Merck KGaA, Darmstadt, Germany’s first study: phase 3 study in Neoplasm MetastasisNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT02625610 · 499 enrolled · United States, Australia, Brazil and more
- Jun 9, 2017Phase 2 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT03184870 · 332 enrolled · United States, Australia, Belgium and more
- Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
- Nov 6, 2017Phase 2 study in Advanced Pancreatic CancerBristol-Myers Squibb · NCT03336216 · 205 enrolled · United States, Canada, Denmark and more
- Apr 12, 2018TTY Biopharm’s first study: phase 2 study in Colorectal NeoplasmsNew to TTY BiopharmTTY Biopharm · NCT03517618 · 41 enrolled · Taiwan
- Jun 5, 2018Leaf Vertical’s first study: phase 2 study in Pancreatic NeoplasmsNew to Leaf VerticalLeaf Vertical · NCT03607643 · 160 enrolled · United States
- Sep 6, 2019Ipsen’s first study: phase 3 study in Metastatic Adenocarcinoma of the PancreasNew to IpsenIpsen · NCT04083235 · 770 enrolled · United States, Australia, Austria and more
- Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
- Feb 9, 2021Cardiff Oncology’s first study: phase 2 study in Pancreatic Ductal AdenocarcinomaNew to Cardiff OncologyCardiff Oncology · NCT04752696 · 41 enrolled · United States
- Feb 20, 2023Jiangsu HengRui Medicine’s first study: phase 3 study in First-line Treatment of Advanced Pancreatic CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05751850 · 778 planned · China
- Oct 25, 2023AbbVie’s first study: phase 2 study in NeoplasmsNew to AbbVieAbbVie · NCT06107413 · 280 enrolled · United States, Belgium, Germany and more
- Jun 25, 20243SBio’s first study: phase 2 study in Colorectal NeoplasmsNew to 3SBio3SBio · NCT06493760 · 130 planned · China
- Jun 24, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712 · 100 planned · United States, Canada, China and more
Ahead
- Dec 2026Primary completion: phase 2 study in NeoplasmsAbbVie · NCT06107413
- Nov 9, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07069712Stomach Neoplasms · United States, Canada, China and more | 2 | Recruiting | AstraZeneca | Nov 9, 2027 | 100 |
| NCT06493760Colorectal Neoplasms · China | 2 | Recruiting | 3SBio | Jun 2025 | 130 |
| NCT06107413Neoplasms · United States, Belgium, Germany and more | 2 | Active, not recruiting | AbbVie | Dec 2026 | 280 |
| NCT05751850First-line Treatment of Advanced Pancreatic Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 30, 2024 | 778 |
| NCT04752696Pancreatic Ductal Adenocarcinoma · United States | 2 | Terminated | Cardiff Oncology | Dec 24, 2024 | 41 |
| NCT04607421Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Mar 1, 2025 | 841 |
| NCT04083235Metastatic Adenocarcinoma of the Pancreas · United States, Australia, Austria and more | 3 | Completed | Ipsen | Jul 23, 2022 | 770 |
| NCT03607643Pancreatic Neoplasms · United States | 2 | UNKNOWN | Leaf Vertical | Jun 30, 2020 | 160 |
| NCT03517618Colorectal Neoplasms · Taiwan | 2 | Completed | TTY Biopharm | Jun 18, 2015 | 41 |
| NCT03336216Advanced Pancreatic Cancer · United States, Canada, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Jun 1, 2023 | 205 |
| NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more | 2 | Terminated | Hoffmann-La Roche | Oct 9, 2025 | 219 |
| NCT03184870Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Apr 6, 2023 | 332 |
| NCT02625610Neoplasm Metastasis · United States, Australia, Brazil and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Sep 13, 2019 | 499 |
| NCT02106650Lymphoma, T-Cell, Peripheral · United States | 2 | Completed | Aurobindo Pharma | Oct 2018 | 36 |
| NCT01930552Neoplasms · China | 1 | Completed | Sanofi | Dec 2014 | 20 |
| NCT01634555Solid Tumors · United States | 2 | Completed | Eli Lilly | Aug 2013 | 29 |
| NCT01494506Pancreatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merrimack Pharmaceuticals | Feb 2014 | 417 |
| NCT01274624Neoplasms · United States | 1 | Completed | Oncolytics Biotech | Feb 2018 | 36 |
| NCT01271166Neoplasms · Australia | 1 | Terminated | Novartis | Aug 2009 | 10 |
| NCT01231802Breast Neoplasms · United States, Russian Federation | 2 | UNKNOWN | Adherex Technologies | Aug 2012 | 140 |
| NCT01227707Colorectal Neoplasms · Italy | 2 | Completed | Hoffmann-La Roche | Aug 2010 | 43 |
| NCT01077739Colorectal Neoplasms · Belgium | 2 | Completed | Hoffmann-La Roche | Jan 2012 | 75 |
| NCT01046864Pyloric Stenosis, Hypertrophic · United States, Canada, France | 1 | Completed | Bristol-Myers Squibb | Jun 2014 | 49 |
| NCT00782041Uterine Neoplasms · Thailand | 2 | Terminated | Sanofi | Aug 2003 | 11 |
| NCT00559455Carcinoma, Hepatocellular · Korea, Republic of | 2 | Completed | Sanofi | Jan 2010 | 38 |
| NCT00499850Adenocarcinoma · Australia | 1 | Completed | Sanofi | Jun 2006 | 18 |
| NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more | 3 | Completed | Sanofi | Mar 2010 | 371 |
| NCT00291785Colorectal Neoplasms · Italy | 2 | Completed | Swedish Orphan Biovitrum | Aug 2007 | 48 |
| NCT00237900Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC · Finland | 2 | Terminated | AstraZeneca | 34 | |
| NCT00233623Colorectal Neoplasms · Italy | 2 | Withdrawn | AstraZeneca | Jan 2006 | 190 |
| NCT00143403Colorectal Neoplasms · Belgium, Denmark, France and more | 3 | Completed | Pfizer | Feb 2008 | 321 |
| NCT00065117Colorectal Neoplasms · United States | 2 | Terminated | AstraZeneca | Feb 2004 | 180 |
| NCT00044785Colorectal Neoplasms · United States | 1 | Terminated | Wellstat Therapeutics | 24 | |
| NCT00040391Colorectal Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb |
How it is read
Names in the registry
- “Leucovorin”, 18 entries
- “leucovorin”, 4 entries
- “Folinic acid”, 3 entries
- “FLOT Chemotherapy”, 1 entry
- “Folinic Acid”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 11 studies
- Neoplasms, 4 studies
- Pancreatic Neoplasms, 4 studies
- Carcinoma, Hepatocellular, 2 studies
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.